2013年10月11日讯 /生物谷BIOON/ --在经过2012年的上升期后,合约研究机构(CRO)行业持续蓬勃发展。一项分析显示今年合约研究机构获得的资金和药物研发成功数目继续上升。这其中一方面原因是自2010年以来,FDA批准新药的标准有所放松,为CRO行业的成长提供了宽松环境。评论人士指出,一些大型、多样化、着重于后期研究的全球性合约研究机构从中受益最多。数据显示2004年世界排名前七的合约研究机构控制着该领域的35%市场,这一数字今天上升到了60%。去年世界排名前四十的合约研究机构总收入达到了136亿美元,比去年增长了10%。(生物谷Bioon.com)
详细英文报道:
After a booming 2012, the CRO industry is likely to grow even further, one analyst projects, riding an increase in biotech funding and drug development successes.
The FDA has been approving more new drugs each year since 2010, ISI‘s Ross Muken points out, and, with biotech venture funding finally showing signs of life, it‘s a good time to be a CRO.
"We believe these trends should benefit the large, diversified, late-phase CROs with global presence and full-service offerings, (which are) far better suited for integrated strategic partnerships," Muken wrote in an investor note.
The keyword there being "large," and Muken expects even more consolidation in an already giant-laden industry. Back in 2004, the world‘s 7 largest CROs controlled 35% of the market, Muken said; they hold a 60% share today.
So far this year, giants like Parexel ($PRXL) and Quintiles ($Q) have used M&A to grow their footprints, and private equity firm KKR spent billions to buy and merge PRA and ReSearch Pharmaceutical Services, creating what it says is the world‘s fourth-largest CRO.
Last year, the 40 biggest CROs in the world hauled in $13.6 billion, according to GlobalData, a 10% annual increase. And while that‘s a hardly a bad sign for the industry at large, in keeping with the CRO world‘s top-heavy DNA, Quintiles and Covance ($CVD) accounted for nearly $6 billion of the total.